Real-world second- and third-line progression-free survival after progression on first-line CDK4/6 inhibitors in HR+/HER2- metastatic breast cancer by PAM50 intrinsic subtype: the SOLTI-1801 CDK-PREDICT study. [PDF]
Tolosa P +25 more
europepmc +1 more source
[Substandard and falsified medical products: 25 years of successful network collaboration among regulatory authorities in the AmericasProdutos médicos de qualidade inferior e falsificados: 25 anos de colaboração bem-sucedida em rede entre autoridades reguladoras da Região das Américas]. [PDF]
Vahos Zambrano J +9 more
europepmc +1 more source
[Research trends on botulinum toxin A in bruxism: a bibliometric analysis]. [PDF]
Vargas-Echeverría SL +2 more
europepmc +1 more source
[Opportunities for intersectoral work in health promotion: Analysis of an urban regeneration program in Chile]. [PDF]
López-Contreras N +2 more
europepmc +1 more source
Relaciones de colaboración con las Comunidades Autónomas [PDF]
García Morales, María Jesús
core +15 more sources
[Prescribing medicines in primary care teams: the challenge of multidisciplinarity and patient safety]. [PDF]
Luzón-Oliver L, Astier-Peña MP.
europepmc +1 more source
[Editorial of the XLV SEMFYC Congress]. [PDF]
Morales MDPC, González AIG, Rodero AC.
europepmc +1 more source
[Infectious tenosynovitis as an unusual focus of septic shock: A case report]. [PDF]
Mora-Aznar M +2 more
europepmc +1 more source
[Communication as a health imperative]. [PDF]
Gonzalez Natal MN +3 more
europepmc +1 more source
[SEFAC's 25th anniversary: consolidating evidence, planning for the future]. [PDF]
Spanish Society of Community Pharmacy Research (SEFAC).
europepmc +1 more source

